Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(2.18)
# 2,841
Out of 5,122 analysts
110
Total ratings
40.21%
Success rate
-2.63%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GHRS GH Research | Maintains: Buy | $35 → $39 | $15.11 | +158.11% | 5 | Jan 6, 2026 | |
| STOK Stoke Therapeutics | Maintains: Buy | $28 → $36 | $31.00 | +16.13% | 5 | Jan 5, 2026 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $25 → $24 | $8.87 | +170.73% | 7 | Nov 6, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $160 → $164 | $137.41 | +19.35% | 17 | Oct 29, 2025 | |
| ATAI AtaiBeckley | Maintains: Buy | $11 → $14 | $3.57 | +292.71% | 4 | Oct 22, 2025 | |
| ANVS Annovis Bio | Maintains: Buy | $17 | $2.47 | +588.26% | 4 | Sep 30, 2025 | |
| CLNN Clene | Maintains: Buy | $83 → $48 | $4.00 | +1,100.00% | 6 | Aug 18, 2025 | |
| CMPS COMPASS Pathways | Maintains: Buy | $15 | $6.18 | +142.91% | 4 | Aug 1, 2025 | |
| CRVO CervoMed | Maintains: Buy | $21 → $27 | $4.83 | +459.01% | 6 | Jul 29, 2025 | |
| BIIB Biogen | Maintains: Buy | $265 → $220 | $181.91 | +20.94% | 21 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $3.63 | +230.58% | 5 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $112 → $80 | $1.47 | +5,342.18% | 7 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $24.37 | +35.41% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $10.84 | +1,283.76% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $35.02 | - | 2 | Jan 31, 2017 |
GH Research
Jan 6, 2026
Maintains: Buy
Price Target: $35 → $39
Current: $15.11
Upside: +158.11%
Stoke Therapeutics
Jan 5, 2026
Maintains: Buy
Price Target: $28 → $36
Current: $31.00
Upside: +16.13%
Zevra Therapeutics
Nov 6, 2025
Maintains: Buy
Price Target: $25 → $24
Current: $8.87
Upside: +170.73%
Neurocrine Biosciences
Oct 29, 2025
Maintains: Buy
Price Target: $160 → $164
Current: $137.41
Upside: +19.35%
AtaiBeckley
Oct 22, 2025
Maintains: Buy
Price Target: $11 → $14
Current: $3.57
Upside: +292.71%
Annovis Bio
Sep 30, 2025
Maintains: Buy
Price Target: $17
Current: $2.47
Upside: +588.26%
Clene
Aug 18, 2025
Maintains: Buy
Price Target: $83 → $48
Current: $4.00
Upside: +1,100.00%
COMPASS Pathways
Aug 1, 2025
Maintains: Buy
Price Target: $15
Current: $6.18
Upside: +142.91%
CervoMed
Jul 29, 2025
Maintains: Buy
Price Target: $21 → $27
Current: $4.83
Upside: +459.01%
Biogen
May 2, 2025
Maintains: Buy
Price Target: $265 → $220
Current: $181.91
Upside: +20.94%
Mar 13, 2025
Maintains: Buy
Price Target: $14 → $12
Current: $3.63
Upside: +230.58%
Jan 6, 2025
Maintains: Buy
Price Target: $112 → $80
Current: $1.47
Upside: +5,342.18%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $24.37
Upside: +35.41%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $10.84
Upside: +1,283.76%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $35.02
Upside: -